Lewy Body Diseases (LBDs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Lewy Body Diseases (LBDs) Market Outlook

Thelansis’s “Lewy Body Diseases (LBDs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lewy Body Diseases (LBDs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Lewy Body Diseases (LBDs) Overview

Lewy body diseases (LBDs) encompass a range of clinical conditions, including Parkinson’s disease (PD), Parkinson’s disease dementia (PDD), and dementia with Lewy bodies (DLB), which collectively exhibit a spectrum of both motor and cognitive symptoms. PD and PDD initially manifest with motor dysfunctions like resting tremors, bradykinesia, and impaired gait, which may progress to cognitive deficits. Conversely, DLB predominantly showcases cognitive impairments, often evolving to encompass Parkinsonian features like those observed in PD. The distinctive pathological hallmark of LBD involves the presence of intraneuronal aggregations of α-synuclein protein, referred to as Lewy bodies. Alongside Lewy body presence, cases of LBD exhibit discernible nigral depigmentation and striatonigral dopaminergic denervation, factors thought to underlie the extrapyramidal manifestations characteristic of clinical parkinsonism. The precise mechanistic significance of Lewy bodies to the neuronal malfunction and degeneration characteristic of LBD remains unresolved. LBD is the second most prevalent form of dementia following Alzheimer’s disease. Onset commonly transpires around age 65, although variations exist concerning earlier or later occurrences. While a definitive cure for LBD remains elusive, therapeutic interventions are available to manage its symptomatic manifestations.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Lewy Body Diseases (LBDs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034